Ładuje się......
Systemic administration of 3-bromopyruvate reveals its interaction with serum proteins in a rat model
BACKGROUND: 3-bromopyruvate (3-BrPA) is a glycolytic inhibitor that affects cancer cells by targeting energy metabolism. Preclinical reports have established that a 1.75 mM dose of 3-BrPA is effective and sufficient to inhibit tumor growth when administered under a loco-regional approach (intraarter...
Zapisane w:
| Główni autorzy: | , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
BioMed Central
2013
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3728150/ https://ncbi.nlm.nih.gov/pubmed/23866825 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-6-277 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|